Chem-/Biotech

Development of TCR T‑cell therapies to combat solid tumors

Captain T Cell GmbH

Captain T Cell develops next-generation immuno-oncology therapies designed to overcome the challenges of solid tumors through a proprietary technology toolbox that enhances T cell efficacy within the tumor microenvironment (TME). This toolbox includes a TGF‑β switch receptor that can be applied to TCR‑T, CAR‑T, and potentially TIL therapies, across autologous, allogeneic, and potentially in vivo engineering modalities. The Company’s autologous lead program, CTC127, is a best-in-class TCR‑T cell therapy targeting MAGE-A4-positive solid tumors and is expected to enter clinical trials in early 2027. In addition, the Company advances a first-in-class allogeneic TCR‑T cell platform that has demonstrated complete responses in vivo. Founded as a spin-off from the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, with Ascenion serving as the MDC’s technology transfer partner, Captain T Cell is supported by leading European life science investors.

TGFS has been a shareholder in the company since 2025. Other investors include Springboard Health Angels, Pluton Asset Holding AG, Sintra Limited, HIL-INVENT, i&i Biotech Fund, and Brandenburg Kapital.